Panitumumab in colon cancer: A review and summary of ongoing trials

Expert Opinion on Biological Therapy

Volumn 6, Issue 11, 2006, Pages 1229-1235

  Wainberg, Zev ^b   Hecht, J Randolph ^a  

^a UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

5 fluoruracil; Bevacizumab; Colorectal cancer; Combination chemotherapy; Epidermal growth factor receptor; Irinotecan; Leucovorin; Oxaliplatin; Panitumumab; Transforming growth factor; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB;

ANTIBODY STRUCTURE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENE OVEREXPRESSION; HUMAN; HYPOMAGNESEMIA; RASH; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33750818148     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.11.1229     Document Type: Review

References (36)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55:10-30.
2. GRAMONT A: Adjuvant therapy of stage II and III colon cancer. Semin. Oncol. (2005) 32:11-14.
3. SALTZ LB, COX DO, BLANKE C et al.: Irinotecan plus fluoruracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2000) 343:905-914.
4. ROTHENBERG ML, OZA AM, GEGELO R et al.: Superiority of oxaliplatin and fluoruracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluoruracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. (2003) 21:2059-2069.
5. COLUCCI G, GEBBIA V, PAOLETTI G et al.: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. (2005) 23:4866-4875.
6. TOURNIGAND C, ANDRE T, ACHILLE E et al.: FOLFIRI followed by FOLFOX or the reverse sequence in advanced colorectal cancer. J. Clin. Oncol. (2004) 22:229-237.
7. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluoruracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2334-2342. First prospective study showing survival benefit with addition of antiangiogenesis agent.
8. KABBINAVAR FF, HURWITZ H, FEHRENBACHER L et al.: Phase II randomized trial comparing bevacizumab plus fluoruracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2004) 21:60-65.
9. HOCHSTER HS: Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Proc. Am. Soc. Clin. Oncol. Orlando, FL, USA (13-17 May 2005).
10. GIANTONIO BJ: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol. Orlando, FL, USA (13-17 May 2005).
11. REAL FX, RETTIG WJ, CHESA PG, MELAMED MR, OLD LJ, MENDELSOHN J: Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res. (1986) 46:4726-4731.
12. YASUI W, SUMIYOSHI H, HATA J et al.: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. (1988) 48(1):137-141.
13. YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. (2001) 2(2):127-137. Review of the EGFR pathway.
14. CIARDELLO F, DAMIANO V, BIANCO R et al.: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. (1996) 88(23):1770-1776.
15. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345. Prospective trial that led to the approval of cetuximab in colorectal cancer.
16. SALTZ LB, MEROPOL NJ, LOEHRER PJ SR, NEEDLE MN, KOPIT J, MAYER RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22(7):1201-1208.
17. LANG I: Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): preliminary safety results (CRYSTAL). Proc. Am. Soc. Clin. Oncol. Atlanta, GA, USA (2-6 June 2006).
18. DIAZ-RUBERO E, TABERNERO JM, VANCUTSEM J et al.: An international Phase II study of Cetuximab in combination with oxaliplatin/5-FU/folinic acid (FOLFOX-4) in the first line treatment of patients with metastatic colorectal cancer expressing EGFR. Proc. Am. Soc. Clin. Oncol. New Orleans, LA, USA (5-8 June 2004).
19. COHEN RB, FALCEY JW, PAULTER VJ et al.: Safety profile of the monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors [abstract]. Proc. Am. Soc. Clin. Oncol. New Orleans, LA, USA (20-23 May 2000).
20. LYNCH DH, YANG XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol. (2002) 29:47-50.
21. YANG XD, JIA XC, CORVALAN J, WANG P, DAVIS CG, JAKOBOVITS A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. (1999) 59:1236-1243.
22. MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21:2787-2799.
23. HECHT JR, PATNAIK A, MALIKI et al.: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc. Am. Soc. Clin. Oncol. New Orleans, LA, USA (5-8 June 2004).
24. FIGLIN RA: ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: Phase I clinical results. Proc. Am. Soc. Clin. Oncol. Orlando, FL, USA (18-21 May 2002).
25. WEINER L: Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. Orlando, FL, USA (13-17 May 2005).
26. MALIK I, HECHT JR, PATNAIK A et al.: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. Orlando, FL, USA (13-17 May 2005).
27. PEETERS M, VAN CUTSEM E, SIENA S et al.: A Phase III, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Proc. Am. Ass. Cancer Res. Washington DC, USA (1-5 April 2006).
28. BERLIN J, MALIK I, PIENS J et al.: Panitumumab therapy with irinotecan, 5-FU and leucovorin in patients with metastatic colorectal cancer. Proc. Eur. Soc. Med. Oncol. Vienna, Austria (29 October-2 November 2004).
29. HECHT JR, MITCHELL E, BARANDA J et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (< 1%) levels of epidermal growth factor receptor (EGFr). ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA (26-28 January 2006).
30. PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell ling cancer. J. Clin. Oncol. (2004) 22(16):3238-3247. Analysis of tumour response and survival following EGFR inhibition.
31. SALTZ L, LENZ H, KINDLER HL et al.: Interim report of randomized Phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. ASCO Gastrointestinal Cancers Symposium. Hollywood, FL, USA (27-29 January 2005).
32. STARLING N, CUNNINGHAM D: Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr. Opin. Oncol. (2004) 16(4):385-390.
33. PRESS MF, SLAMON DJ, FLOM KJ et al.: Evaluation of HER-2 neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. (2002) 20(14):3095-3105.
34. BERLIN J, NEUBAUER M, SWANSON P et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA (26-28 January 2006).
35. SCARTOZZI M, BEARZI I, BERARDI R, MANDOLESI A, FABRIS G, CASCINU S: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol. (2004) 22(23):4772-4778.
36. LIEVRE A, BACHET JB, LE CORRE D et al.: KRAS mutation starus is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66(8):3992-3995.